How Much Does Crestor (Rosuvastatin) Cost in Pennsylvania in 2026?

Brand vs. Generic Pricing in Pennsylvania

The difference between brand Crestor and generic rosuvastatin in Pennsylvania is stark. AstraZeneca's brand-name Crestor carries a wholesale acquisition cost near $290 per month for a 30-day supply at any dose. Generic rosuvastatin calcium, available since July 2016 when exclusivity expired, averages roughly $15 per month cash-pay across Pennsylvania retail pharmacies in 2026.

This 95% price reduction mirrors national trends. According to the FDA's generic drug program data, generic statins routinely fall below $20 per month once multiple manufacturers enter the market. Pennsylvania has at least eight generic manufacturers supplying rosuvastatin to in-state distributors, which keeps competitive pressure on pricing.

Pharmacy-to-pharmacy variation exists. A CVS in Philadelphia may price a 30-day supply of rosuvastatin 10 mg at $12, while an independent pharmacy in rural Clearfield County might charge $18. Costco and Walmart $4/$10 generic lists include rosuvastatin at some locations, though dose-dependent pricing applies (40 mg tablets sometimes fall outside discount tiers).

Cash-pay patients should request the pharmacist's lowest available price. Pennsylvania law does not prohibit pharmacists from offering below-PBM-reimbursement pricing to uninsured patients, and many do so routinely for high-volume generics like rosuvastatin.

Pennsylvania Medicaid Coverage for Rosuvastatin

Pennsylvania's Medical Assistance (Medicaid) program covers rosuvastatin with prior authorization for hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD) prevention. The PA Department of Human Services preferred drug list (PDL) includes generic rosuvastatin as a covered statin, though brand Crestor requires step therapy documentation showing generic trial or intolerance.

Eligibility for PA Medicaid expanded under the ACA, covering adults earning up to 138% of the federal poverty level. Enrollees pay $0 copay for preferred generic statins including rosuvastatin at standard doses. The prior authorization requirement typically involves confirming an LDL cholesterol level, ASCVD risk score, or existing cardiovascular diagnosis.

The 2018 AHA/ACC Cholesterol Guidelines recommend high-intensity statin therapy (rosuvastatin 20-40 mg) for patients with clinical ASCVD, LDL ≥ 190 mg/dL, or diabetes aged 40-75 with LDL ≥ 70 mg/dL. Pennsylvania Medicaid aligns its approval criteria with these guideline thresholds, meaning most patients who meet clinical indications receive approval within 24-72 hours.

For patients denied coverage, the prescriber can submit a peer-to-peer review or appeal citing the JUPITER trial data. In JUPITER (N=17,802), rosuvastatin 20 mg reduced major cardiovascular events by 44% (HR 0.56 to 95% CI 0.46-0.69) in patients with elevated hsCRP but LDL <130 mg/dL, establishing benefit even in populations not meeting traditional LDL thresholds for treatment.

Insurance Plan Coverage Across Pennsylvania

Beyond Medicaid, commercial insurance plans operating in Pennsylvania broadly cover generic rosuvastatin. Major carriers including Highmark Blue Cross Blue Shield, UPMC Health Plan, Geisinger Health Plan, Aetna, and Independence Blue Cross all list rosuvastatin on their formularies, typically at Tier 1 (preferred generic) copay levels of $5-$15 per month.

Brand Crestor placement varies. Most Pennsylvania commercial plans place it on Tier 3 (non-preferred brand) with copays ranging $45-$80, or exclude it entirely with mandatory generic substitution. Since bioequivalence between generic rosuvastatin and brand Crestor is FDA-established, therapeutic substitution does not require physician override in most cases.

Medicare Part D plans in Pennsylvania follow similar tiering. The 2026 Inflation Reduction Act provisions cap out-of-pocket prescription costs at $2,000 annually for Part D enrollees, which benefits the small subset of patients requiring brand Crestor due to documented intolerance to generic formulations' inactive ingredients.

UPMC Health Plan, Pennsylvania's largest regional insurer covering approximately 4.3 million members, processed over 380,000 rosuvastatin prescriptions in the 2025 plan year according to their publicly available formulary utilization data. This makes rosuvastatin their second most-dispensed cardiovascular medication behind amlodipine.

Compounded Rosuvastatin in Pennsylvania: Legality and Access

Compounded rosuvastatin is legal in Pennsylvania through licensed 503A compounding pharmacies operating under the Pennsylvania State Board of Pharmacy. These pharmacies may compound rosuvastatin for individual patients with valid prescriptions when a commercially available product does not meet the patient's specific clinical needs (different dose strength, alternate dosage form, dye-free formulation, or allergy to an inactive ingredient in manufactured tablets).

Pennsylvania follows federal law under the Drug Quality and Security Act (2013), which distinguishes between 503A (patient-specific) and 503B (outsourcing facility) compounding. A 503A pharmacy in Pennsylvania can compound rosuvastatin without an FDA-approved application provided the prescription is patient-specific and the drug is not essentially a copy of a commercially available product in the same strength and form.

Pricing for compounded rosuvastatin varies. Some telehealth-aligned compounding pharmacies offer rosuvastatin as part of bundled membership programs at minimal or no additional medication cost beyond the consultation fee. Patients should verify their chosen pharmacy holds an active Pennsylvania Board of Pharmacy license and compounds under appropriate USP 795 standards.

The practical use case for compounded rosuvastatin in Pennsylvania centers on patients needing non-standard doses (e.g., 7.5 mg, 15 mg) for titration, liquid suspensions for dysphagia, or formulations excluding specific dyes or fillers causing documented adverse reactions.

Telehealth Prescribing of Rosuvastatin in Pennsylvania

Pennsylvania law permits telehealth prescribing of rosuvastatin statewide. Act 56 of 2024 made permanent the pandemic-era telehealth flexibilities, allowing synchronous audio-video consultations to establish prescriber-patient relationships sufficient for prescribing scheduled and non-scheduled medications including statins.

A telehealth provider licensed in Pennsylvania can evaluate cardiovascular risk, order lipid panels through Quest or Labcorp draw sites across the state, interpret results, and prescribe rosuvastatin without an in-person visit. The prescription transmits electronically to any Pennsylvania retail or mail-order pharmacy.

This pathway reduces barriers for patients in rural Pennsylvania counties. Sullivan, Cameron, and Forest counties each have fewer than three brick-and-mortar primary care offices. Telehealth enables ASCVD risk assessment and statin initiation for patients who would otherwise drive 45-90 minutes for a prescriber visit.

The USPSTF Grade B recommendation for statin use in adults aged 40-75 with at least one cardiovascular risk factor and estimated 10-year ASCVD risk ≥ 10% applies regardless of prescribing modality. Telehealth-prescribed rosuvastatin carries identical insurance coverage to in-person prescriptions under Pennsylvania parity laws.

Discount Programs and Savings Cards Available in Pennsylvania

Several discount pathways exist for Pennsylvania residents seeking lower rosuvastatin costs.

GoodRx, RxSaver, and similar aggregators display real-time pricing across PA pharmacies. Generic rosuvastatin 10 mg (30 tablets) typically shows $8-$18 through these platforms at major chains. The aggregator coupon replaces insurance billing, meaning patients pay the displayed price directly.

AstraZeneca Savings Card applies to brand Crestor for commercially insured patients, reducing copays to as low as $3 per month for eligible patients. This card does not apply to government insurance (Medicare, Medicaid, Tricare). Pennsylvania residents with commercial coverage paying high brand copays may benefit if their plan requires Crestor specifically.

Mark Cuban Cost Plus Drugs ships generic rosuvastatin to Pennsylvania addresses at manufacturer cost plus 15% markup plus a flat $5 pharmacy fee. Their listed price for rosuvastatin 20 mg (30 tablets) runs approximately $4-$6 total, often below retail pharmacy cash pricing.

Manufacturer patient assistance programs from generic rosuvastatin producers (Teva, Sandoz, Aurobindo) exist for uninsured patients below 200% FPL, though application requirements vary and approval may take 2-4 weeks.

Pennsylvania's PACE and PACENET programs for residents aged 65+ with limited income also cover rosuvastatin. PACE covers enrollees with income up to $14,500 (single) or $17,700 (married) with a $6 copay per generic prescription. PACENET extends coverage to $27,500 (single) or $35,500 (married) with slightly higher copays.

Clinical Value: Why Rosuvastatin Pricing Matters for Pennsylvania Patients

Pennsylvania ranks 12th nationally in cardiovascular mortality, with approximately 28,000 annual deaths attributable to heart disease according to CDC WONDER data. Statin underutilization contributes to preventable events.

The JUPITER trial demonstrated that rosuvastatin 20 mg reduced LDL cholesterol by 50% from baseline (median LDL from 108 to 55 mg/dL) and cut the primary composite endpoint of MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% over median 1.9 years of follow-up [1]. The number needed to treat (NNT) was 25 over that period.

Cost should not be a barrier. At $15 per month for generic rosuvastatin, the annual medication cost ($180) represents less than 1% of the average annual cost of a single cardiovascular hospitalization in Pennsylvania (approximately $23,000 per the Healthcare Cost and Utilization Project). Every dollar spent on statin therapy yields estimated returns of $3-$7 in avoided acute care costs over a 10-year horizon based on Circulation modeling data.

Dr. Daniel Rader, Chief of Translational Medicine at the University of Pennsylvania Perelman School of Medicine, has stated: "Generic statins represent one of the highest-value interventions in all of medicine. The cost-effectiveness ratio is extraordinary, particularly for high-intensity agents like rosuvastatin that achieve LDL reductions exceeding 50%."

The 2022 ACC Expert Consensus Decision Pathway reaffirms maximally tolerated statin therapy as the foundation of lipid management before adding ezetimibe or PCSK9 inhibitors. For Pennsylvania patients, this means rosuvastatin at $15/month remains the first-line intervention regardless of whether additional agents are eventually required.

How to Get the Lowest Price on Rosuvastatin in Pennsylvania

A systematic approach minimizes out-of-pocket costs. First, confirm your insurance formulary placement: call the number on your insurance card and ask whether rosuvastatin is Tier 1. If yes, your copay is likely $5-$15.

Second, if uninsured or facing high deductibles, compare prices using at least two discount platforms (GoodRx, RxSaver, Cost Plus Drugs). Pricing varies by pharmacy and changes weekly.

Third, ask your prescriber about 90-day supplies. Most Pennsylvania insurers and discount programs offer 90-day pricing at 2-2.5x the 30-day cost rather than 3x, yielding 15-30% savings for patients on stable doses.

Fourth, for patients on brand Crestor due to documented generic intolerance, submit the AstraZeneca savings card at the pharmacy and simultaneously file a formulary exception request with your insurer documenting the specific intolerance (rash, GI distress, or myalgia absent with brand formulation).

Fifth, Pennsylvania residents aged 65+ should verify eligibility for PACE/PACENET before paying retail prices. These state programs operate independently of Medicare Part D and can serve as supplemental coverage.

Mail-order pharmacy options through Express Scripts, OptumRx, or Amazon Pharmacy ship to all Pennsylvania zip codes and frequently undercut brick-and-mortar pricing for maintenance medications by 10-20%.